Connaughton of Halozyme sells $150k in stock

Director Bernadette Connaughton of Halozyme Therapeutics Inc (NASDAQ:HALO) sold 2,000 shares of common stock on October 1, 2025, for a total of approximately $150,481. The sale comes as Halozyme trades near its 52-week high of $79.50, having delivered an impressive 56.75% return year-to-date. According to InvestingPro analysis, the company maintains a "GREAT" financial health score.

The sales were executed in two transactions. The first involved 1,500 shares sold at a weighted average price of $75.086, with prices ranging from $74.64 to $75.55. The second transaction involved 500 shares sold at a weighted average price of $75.704, with prices ranging from $75.64 to $75.92.

Following the transactions, Connaughton directly owns 44,952 shares of Halozyme Therapeutics . The sales were made pursuant to a written trading plan adopted on May 29, 2025, in accordance with Rule 10b5-1.The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.

In other recent news, Halozyme Therapeutics announced its plans to acquire Elektrofi for $750 million, aiming to expand its drug delivery technology. The deal includes additional milestone payments of up to $150 million based on future product regulatory approvals and is expected to close in the fourth quarter of 2025. On the earnings front, Benchmark has raised its price target for Halozyme to $90, citing strong earnings results for the first half of 2025 and positive financial guidance. H.C. Wainwright also increased its price target to $85, following the FDA approval of Merck & Co.’s subcutaneous Keytruda, which could drive significant conversion from intravenous administration. Meanwhile, Citizens JMP reaffirmed its Market Outperform rating and a $91 price target, viewing recent CMS guidance on Medicare drug price negotiations as favorable for Halozyme’s ENHANZE technology. Goldman Sachs adjusted its price target to $56, reflecting an analysis of the Inflation Reduction Act’s impact on Part B drugs. These developments highlight a period of significant activity and optimism surrounding Halozyme’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.